$140.09
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Overview
52-week range
$101
$176
52% of range
Avg surprise (last 3)
+10.1%
Avg reaction (last 2)
+1.7%
50% positive
Latest IV / EM
60%
EM ±13.7% · $140 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $0.48 | $0.38 | +26.3% | +23.1% | +6.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.26 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $0.37 | $0.40 | -7.5% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $0.39 | $0.35 | +11.4% | — | -2.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.01 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.30 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.35 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Jul 28, 2026 | Jun/2026 | BMO | $0.45 | $0.37 | +21.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $86M | — | $88M | $91M | $78M | — | $77M | $77M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $16M | — | $17M | $14M | $7M | — | $-8M | $5M |
| Net income | $8M | — | $15M | $15M | $6M | — | $-654,000 | $6M |
| EPS (diluted) | $0.15 | — | $0.26 | $0.26 | $0.10 | — | $-0.01 | $0.10 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $583M | $566M | $749M | $709M | $697M | $757M | $784M | $809M |
| Inventory | $179M | $170M | $160M | $156M | $153M | $143M | $182M | $191M |
| Total current assets | $1.16B | $1.14B | $1.10B | $1.06B | $1.03B | $1.07B | $1.13B | $1.16B |
| Total assets | $2.93B | $2.95B | $2.92B | $2.90B | $2.85B | $2.83B | $2.83B | $2.87B |
| Long-term debt | $547M | $542M | $538M | — | — | $526M | — | — |
| Total liabilities | $825M | $844M | $841M | $840M | $867M | $857M | $814M | $882M |
| Total equity | $2.11B | $2.11B | $2.08B | $2.06B | $1.99B | $1.97B | $2.02B | $1.98B |